New York (Reuters) - Hedge fund Paulson & Co has amassed a large stake in Allergan Inc of more than 6 million shares and is supportive of a deal between the Botox maker and Valeant Pharmaceuticals Inc , people familiar with the matter said on Wednesday.
The position is expected to rank the prominent U.S. hedge fund, led by John Paulson, among the top 10 to 15 holders of ALLERGAN (AGN.NY) according to Thomson Reuters shareholder data as of March 31.
Paulson's new position in Allergan could give Valeant a boost, as the company tries to drum up support from at least 25 percent of Allergan shareholders so that it can call a special meeting.
Valeant and its ally, Bill Ackman's Pershing Square Capital Management, are seeking to call a meeting to elect new directors to Allergan's board, which could pave the way for a takeover of the company.
Valeant has taken its offer directly to Allergan shareholders after the Botox maker has rejected its latest $53 billion takeover bid, comprised of $72 in cash and 0.83 share of Valeant stock.
(Reporting by Nadia Damouni and Olivia Oran in New York; Editing by Marguerita Choy)
Relacionados
- Madina ve "una buena decisión" que Magdalena Álvarez haya dimitido como vicepresidenta del BEI
- A Madina le parece "una buena decisión" que Magdalena Álvarez haya dimitido como vicepresidenta del BEI
- Floriano (PP) dice que la dimisión de Magdalena Álvarez responde a sus "enredos en los ERE de Andalucía"
- Floriano (PP) dice que la dimisión de Magdalena Álvarez responde a sus "enredos en los EREs de Andalucía"
- El PA ve "razonable" la dimisión de Magdalena Álvarez como vicepresidenta del BEI, aunque considera que llega "tarde"
